摘要
可溶性尿激酶型纤溶酶原激活物受体(su PAR)作为一种新型损伤标志物,现已广泛应用于感染性疾病、肿瘤、心血管疾病、自身免疫性疾病等研究。近年来有学者提出su PAR在多种肾疾病的发生发展中发挥重要作用。文章主要就su PAR与局灶节段性肾小球硬化(FSGS)、微小病变肾病(MCD)、Ig A肾病(Ig AN)、糖尿病肾病(DKD)、慢性肾病(CKD)、急性肾损伤(AKI)等多种肾疾病的研究进展进行综述。
Soluble urokinase-type plasminogen activator receptor（suPAR）,a new injury biomarker,is widely used in research of infectious diseases,cancer,cardiovascular diseases,autoimmune diseases,etc. In recent years,suPAR has been suggested to play an important role in various renal diseases. This review focuses on studies of suPAR in renal diseases and update,which will provide new clues for the diagnosis and treatment of renal diseases.
作者
周雨菁
肖晓燕
ZHOU Yu-jing;XIAO Xiao-yan(Department of Endocrinology;Department of Nephrology,Qilu Hospital of Shandong University,Jinan 250012,Shandong,China)
出处
《医学研究生学报》
CAS
北大核心
2018年第7期768-772,共5页
Journal of Medical Postgraduates
基金
国家自然科学基金(81100520)
